![Steven Kelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Kelly
Director/Board Member at
ARTELO BIOSCIENCES, INC.
Net worth: 36 $ as of 2026-06-29
Profile
Steven Kelly was the founder of CTx Operations, Inc., founded in 2018, serving as President & Chief Executive Officer from 2018 to 2025.
Mr. Kelly is currently an Independent Director at Artelo Biosciences, Inc. since 2017.
Former positions include President & Chief Executive Officer at Innovive Pharmaceuticals, Inc. from 2004 to 2010; Chief Commercial Officer at BioVex, Inc. from 2010 to 2011; Chief Executive Officer at Theracrine, Inc. from 2011 to 2012; Principal at Kelly Bioconsulting LLC from 2012 to 2018; President, Chief Executive Officer & Director at Carisma Therapeutics, Inc. from 2018 to 2025; Chief Executive Officer at Carisma Therapeutics, Inc. from 2025 to 2026; and President & Chief Executive Officer at Pinteon Therapeutics, Inc. from 2014 to 2015.
Education includes an MBA from Cornell University and an undergraduate degree from the University of Oregon.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-07-16 | 47 ( 0% ) | 36 $ | 2026-07-30 | |
| 2025-05-30 | 0 ( -.--% ) | - $ | 2026-06-29 |
Steven Kelly active positions
| Companies | Position | Start |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Director/Board Member | 2017-05-01 |
Former positions of Steven Kelly
| Companies | Position | End |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Chief Executive Officer | 2025-12-31 |
| CARISMA THERAPEUTICS, INC. | Chief Executive Officer | 2025-11-14 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Chief Executive Officer | 2025-10-31 |
Kelly Bioconsulting LLC
 Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Corporate Officer/Principal | 2017-12-31 |
Pinteon Therapeutics, Inc.
 Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Chief Executive Officer | 2015-06-30 |
Training of Steven Kelly
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
50
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theracrine, Inc.
 Theracrine, Inc. BiotechnologyHealth Technology Develops anti-metastatic drugs for cancer therapeutics | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
Kelly Bioconsulting LLC
Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
- Stock Market
- Insiders
- Steven Kelly
